Published in JAMA Oncology · View the paper (DOI)
A new study by researchers at Dana-Farber Cancer Institute found that patients with cancer and a weakened immune system who receive immunotherapies are more likely to experience severe COVID-19. The study also found that patients treated with other systemic treatments have milder symptoms, but still face increased risk of complications.
Coverage from 2 institutions